Dr Chris Bailey is Development Director. Chris was previously responsible for all pre-clinical science (vaccines, rDNA products, gene therapies, small molecules) at Medeva. Dr Bailey has extensive product development experience, dealing with scientific and regulatory issues that arose in manufacturing, pre-clinical and clinical areas of the viral vaccine development with the successful pan-European approval of Hepacare, a novel Hepatitis B vaccine at Medeva prior to its acquisition by Celltech.
Prime responsibilities are:
- Development strategy
- Programme management
- Liaison with clinical, regulatory and manufacturing services
Education
- BSc (1st Class Honours) Biochemistry, University of Aberdeen
- PhD, Department of Genetics, University of Cambridge
Experience
- Medeva Development, integrating with Celltech Chiroscience Development:
- Director of Pre-clinical Sciences
- Director of Pre-clinical Development and New Drug Management
- Head of Pre-clinical Development Department
- Head of Pre-clinical Studies for the Hepatitis B Project
- Project Manager
- Project Manager, Celltech Ltd
- Head of Genetics Department, Celltech Joint Venture Company Apcel Ltd
- Senior Research Scientist, Beecham Pharmaceuticals
- Development Scientist, Beecham Pharmaceuticals
- Department of Genetics, University of Cambridge
|
